Driver oncogenes such as EGFR in lung cancer somatic mutations possess intense oncogenic potential known as “oncogenic addiction,” leading to significant therapeutic effects from a single molecularly targeted drug. The gene discussed is EGFR; the disease is lung carcinoma.